| Literature DB >> 33059654 |
Nozomu Motono1, Shun Iwai2, Yoshihito Iijima2, Katsuo Usuda2, Hidetaka Uramoto2.
Abstract
BACKGROUND: The relationship between operative invasiveness and the prognosis in non-small cell lung cancer (NSCLC) patients who have undergone surgery has been controversial.Entities:
Keywords: Non-small cell lung cancer; Operative invasiveness; Video-assisted thoracic surgery
Mesh:
Substances:
Year: 2020 PMID: 33059654 PMCID: PMC7558745 DOI: 10.1186/s12890-020-01264-x
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Patient characteristics
| Gender (male / female) | 281 (61%) / 182 (39%) |
| Age (y.o.), median (range) | 68.4 (34–87) |
| Smoking index, median (range) | 600 (0–3600) |
| CEA (ng/ml), median (range) | 3.6 (0.5–236) |
| Charlson comorbidity index (0 / 1 / 2 / 3 / 4) | 282 (61%) / 108 (23.2%) / 62 (13.4%) / 9 (2%) / 2(0.4%) |
| Wound length (cm), median (range) | 8 (3–25) |
| Approach (C-VATS / Hybrid / Thoracotomy) | 77 (17%) / 321 (69%) / 65 (14%) |
| Operative procedure (Seg / Lob / Bilob / Pneumo) | 26 (6%) / 409 (88%) / 10 (2%) / 18 (4%) |
| Operation time (min), median (range) | 230 (67–674) |
| Histology (Ad / Sq / AdSq / LCNEC / Large / Pleo) | 350 (76%) / 91 (19.6%) / 8 (1.6%) / 9 (1.8%) / 3 (0.6%) / 2 (0.4%) |
| Differentiation (G1 / 2 / 3 / 4) | 173 (37.4%) / 203 (43.8%) / 75 (16.2%) / 12 (2.6%) |
| Ly (0 / 1) | 271 (58.5%) / 192 (41.5%) |
| V (0 / 1) | 236 (51%) / 225 (49%) |
| pStage (IA / IB / IIA / IIB / IIIA) | 225 (48.5%) / 101 (21.8%) / 48 (10.4%) / 43 (9.3%) / 46 (10%) |
| Preoperative CRP (ng/ml), median (range) | 0.1 (0.02–14.89) |
| Postoperative CRP (ng/ml), median (range) | 13.39 (0.66–36.28) |
| Clavien-Dindo grade (0 / 1 / 2 / 3a / 3b) | 340 (73.4%) / 20 (4.3%) / 45 (9.7%) / 53 (11.4%) / 5 (1.2%) |
CEA carcinoembryonic antigen, VATS video-assisted thoracic surgery, Seg segmentectomy, Lob lobectomy, Bilob bilobectomy, Pneumo pneumonectomy, Ad adenocarcinoma, Sq squamous cell carcinoma, AdSq adenosquamous cell carcinoma, LCNEC large cell neuroendocrine cell carcinoma, Large large cell carcinoma, Pleo pleomorphic cell carcinoma, G grade, Ly lymphatic invasion, V vascular invasion; pStage pathological stage, CRP C-reactive protein
The differences of perioperative factors by operative approach
| Variables | VATS | Thoracotomy | |
|---|---|---|---|
| Wound length | 7 (3–18) | 20 (8–25) | < 0.01 |
| Operation time | 203 (67–674) | 320 (154–672) | < 0.01 |
| Postoperative CRP | 12.2 (0.66–36.28) | 20.58 (6.4–33.72) | < 0.01 |
VATS video-assisted thoracic surgery, CRP C-reactive protein
Correlation coefficient
| Variable | Correlation coefficient | |
|---|---|---|
| Wound length vs Postoperative CRP | 0.399 | < 0.01 |
| Operation time vs Postoperative CRP | 0.544 | < 0.01 |
| Operation time vs Wound length | 0.432 | < 0.01 |
CRP C-reactive protein
Fig. 1a Relapse-free survival rate in the VATS group was significantly longer than in the thoracotomy group. b Relapse-free survival in patients with a wound length of ≤10 cm was significantly longer than that in patients with a wound length of > 10 cm. c Relapse-free survival in patients with an operation time of ≤248 min was significantly longer than that in patients with an operation time of > 248 min. d Relapse-free survival in patients with a preCRP level of ≤0.14 was significantly longer than that in patients with a preCRP level of > 0.14. e Relapse-free survival in patients with a postCRP level of ≤14.49 was significantly longer than that in patients with a postCRP level of > 14.49
Fig. 2a Overall survival rate in the VATS group was significantly longer in comparison to the thoracotomy group. b Overall survival in the wound length ≤ 10 cm group was significantly longer than that in the wound length > 10 cm. c Overall survival in the operation time ≤ 248 min group was significantly longer than that in the operation time > 248 min group. d Overall survival in the preCRP ≤0.14 group was significantly longer than that in the preCRP > 0.14 group. e Overall survival in the postCRP ≤14.49 group was significantly longer than that in the postCRP > 14.49 group
Cox proportional hazard analyses for factors affecting relapse free survival
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| Variables | HR (95%CI) | HR (95%CI) | |||
| Gender | female | 1 | |||
| male | 1.92 (1.27–2.99) | < 0.01 | |||
| Age | < 70y | 1 | |||
| ≥ 70y | 1.11 (0.75–1.63) | 0.57 | |||
| Charlson comorbidity index | 0–2 | 1 | |||
| 3–4 | 1.29 (0.41–7.85) | 0.70 | |||
| Smoking status | never | 1 | |||
| Former / current | 2.10 (1.38–3.28) | < 0.01 | |||
| CEA | ≤ 5 ng/ml | 1 | 1 | ||
| > 5 ng/ml | 1.98 (1.36–2.89) | < 0.01 | 1.58 (1.05–2.38) | 0.02 | |
| Operative approach | Thoracotomy | 1 | |||
| VATS | 0.57 (0.33–0.82) | < 0.01 | |||
| Wound length | ≤ 10 cm | 1 | |||
| > 10 cm | 2.07 (1.37–3.08) | < 0.01 | |||
| Operation time | ≤ 248 min | 1 | |||
| > 248 min | 1.62 (1.09–2.44) | < 0.01 | |||
| Operative procedure | Seg / Lob | 1 | |||
| Bilob / Pneumo | 1.99 (1.01–3.55) | 0.04 | |||
| pStage | I | 1 | 1 | ||
| II - IIIA | 4.59 (3.13–6.78) | < 0.01 | 2.57 (1.60–4.18) | < 0.01 | |
| Histology | Ad | 1 | |||
| Non-Ad | 1.32 (0.86–1.97) | 0.19 | |||
| Differentiation | G1 | 1 | |||
| G2 – G4 | 2.09 (1.38–3.24) | < 0.01 | |||
| Ly | absent | 1 | |||
| present | 4.38 (2.25–9.01) | < 0.01 | |||
| V | absent | 1 | 1 | ||
| present | 3.26 (2.16–5.05) | < 0.01 | 1.95 (1.15–3.38) | 0.01 | |
| preCRP | ≤ 0.14 | 1 | 1 | ||
| > 0.14 | 2.80 (1.91–4.17) | < 0.01 | 1.91 (1.22–3.00) | < 0.01 | |
| postCRP | ≤ 14.49 | 1 | |||
| > 14.49 | 1.83 (1.24–2.72) | < 0.01 | |||
| Clavien-Dindo grade | 0 - I | 1 | |||
| II - IIIb | 1.36 (0.86–2.09) | 0.17 | |||
CEA carcinoembryonic antigen, VATS video-assisted thoracic surgery, Seg segmentectomy, Lob lobectomy, Bilob bilobectomy, Pneumo pneumonectomy, pStage pathological stage,
Ly lymphatic invasion, V vascular invasion, preCRP preoperative C-reactive protein, postCRP postoperative C-reactive protein
Cox proportional hazard analyses for factors affecting overall survival
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| Variables | HR (95%CI) | HR (95%CI) | |||
| Gender | female | 1 | |||
| male | 3.32 (1.89–6.31) | < 0.01 | |||
| Age | < 70y | 1 | |||
| ≥ 70y | 1.08 (0.67–1.70) | 0.74 | |||
| Charlson comorbidity index | 0–2 | 1 | |||
| 3–4 | 1.37 (0.22–4.38) | 0.67 | |||
| Smoking status | never | 1 | 1 | ||
| Former /current | 4.12 (2.31–8.03) | < 0.01 | 2.36 (1.07–5.56) | 0.03 | |
| CEA | ≤ 5 ng/ml | 1 | |||
| > 5 ng/ml | 1.88 (1.20–2.95) | < 0.01 | |||
| Operative approach | Thoracotomy | 1 | |||
| VATS | 0.45 (0.28–0.75) | < 0.01 | |||
| Wound length | ≤ 10 cm | 1 | |||
| > 10 cm | 2.41 (1.51–3.79) | < 0.01 | |||
| Operation time | ≤ 248 min | 1 | |||
| > 248 min | 1.84 (1.09–3.23) | 0.02 | |||
| Operative procedure | Seg / Lob | 1 | |||
| Bilob / Pneumo | 2.98 (1.48–5.41) | < 0.01 | |||
| pStage | I | 1 | 1 | ||
| II - IIIA | 4.83 (3.05–7.82) | < 0.01 | 3.26 (1.77–6.08) | < 0.01 | |
| Histology | Ad | 1 | |||
| Non-Ad | 1.60 (0.98–2.55) | 0.05 | |||
| Differentiation | G1 | 1 | |||
| G2 – G4 | 1.92 (1.19–3.17) | < 0.01 | |||
| Ly | absent | 1 | |||
| present | 1.95 (1.24–3.11) | < 0.01 | |||
| V | absent | 1 | 1 | ||
| present | 3.36 (2.06–5.69) | < 0.01 | 2.80 (1.49–5.38) | < 0.01 | |
| preCRP | ≤ 0.14 | 1 | |||
| > 0.14 | 2.85 (1.80–4.61) | < 0.01 | |||
| postCRP | ≤ 14.49 | 1 | |||
| > 14.49 | 2.20 (1.35–3.69) | < 0.01 | |||
| Clavien-Dindo grade | 0 - I | 1 | |||
| II - IIIb | 1.45 (0.83–2.43) | 0.17 | |||
CEA carcinoembryonic antigen, VATS video-assisted thoracic surgery, Seg segmentectomy, Lob lobectomy, Bilob bilobectomy, Pneumo pneumonectomy, pStage pathological stage,
Ly lymphatic invasion, V vascular invasion, preCRP preoperative C-reactive protein, postCRP postoperative C-reactive protein